면역분석 시장 예측(-2032년) : 제품 유형, 플랫폼, 기술, 시료 유형, 용도, 최종 사용자, 지역별 분석

According to Stratistics MRC, the Global Immunoassay Market is accounted for $40.74 billion in 2025 and is expected to reach $69.38 billion by 2032 growing at a CAGR of 7.9% during the forecast period. An immunoassay is a biochemical test that measures the presence or concentration of a substance, typically in a liquid sample, using the reaction between an antigen and an antibody. It is widely used in diagnostics, pharmaceutical research, and environmental testing to detect hormones, drugs, proteins, or pathogens. Immunoassays offer high sensitivity and specificity, making them essential tools in disease diagnosis, therapeutic drug monitoring, and biomedical research applications.

According to the National Development Council, the geriatric population of Taiwan will reach 19.9% in 2025, 23.9% in 2030, and 27.3% in 2035.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions is driving demand for immunoassay testing. Immunoassays play a crucial role in disease diagnosis, monitoring, and treatment management, leading to their widespread adoption in clinical settings. Additionally, advancements in assay technologies have improved sensitivity and specificity, enhancing their application in diagnostic laboratories. The aging population and rising incidence of infectious diseases further contribute to market expansion.

Restraint:

High cost of instruments and reagents

High initial investment requirements for advanced assay systems deter small and medium healthcare providers from adopting these technologies. The recurring expenses of reagents and consumables add to the overall operational cost, limiting accessibility, particularly in developing economies. Additionally, stringent regulatory standards necessitate expensive validation processes, increasing financial burden on manufacturers. Cost constraints also hinder widespread adoption of automated immunoassay analyzers in resource-limited healthcare settings.

Opportunity:

Point-of-Care testing demand

POC immunoassay systems enable rapid and accurate disease diagnosis, facilitating timely medical intervention. The convenience and efficiency of POC testing are driving adoption across hospitals, clinics, and home healthcare settings. Technological advancements in portable immunoassay devices are enhancing accessibility, especially in remote and underserved regions. Rising awareness regarding early disease detection is further boosting demand for POC immunoassays. Market participants are investing in innovation to develop user-friendly and cost-effective POC testing solutions.

Threat:

Limited standardization

Variability in assay performance can lead to inconsistencies in diagnostic results, affecting clinical decision-making. Laboratories and healthcare providers struggle with interoperability issues when integrating immunoassay systems from different manufacturers. The absence of universally accepted assay protocols complicates quality control efforts, raising concerns about test reliability. Regulatory bodies emphasize standardization, but achieving harmonization across diverse technologies remains complex.

Covid-19 Impact

The COVID-19 pandemic significantly boosted the immunoassay market due to the urgent need for rapid and accurate diagnostic testing. Demand surged for antibody and antigen tests to detect and monitor the virus, driving innovation and increased production capacity. Governments and healthcare organizations invested heavily in diagnostics, expanding market size and accelerating regulatory approvals. Post-pandemic, the heightened awareness of infectious diseases and preparedness for future outbreaks continue to sustain growth and technological advancement in the immunoassay sector.

The reagents & kits segment is expected to be the largest during the forecast period

The reagents & kits segment is expected to account for the largest market share during the forecast period, due to its critical role in immunoassay testing procedures. High consumption rates of reagents in hospitals, diagnostic laboratories, and research institutions contribute to its significant market share. The rising number of diagnostic tests globally is increasing the demand for immunoassay reagents. Continuous advancements in reagent formulations are improving assay sensitivity, fuelling their widespread adoption.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals & clinics segment is predicted to witness the highest growth rate, driven by increasing patient volumes and diagnostic needs. Immunoassays are widely used in hospitals for disease screening, therapeutic monitoring, and emergency diagnostics. The integration of automated immunoassay analyzers in hospital laboratories is improving efficiency and accuracy. Rising healthcare investments and the demand for high-throughput testing solutions are propelling market expansion.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its rapidly expanding healthcare sector. Increasing government investments in medical infrastructure are fuelling market growth across key countries such as China, India, and Japan. Rising awareness regarding early disease diagnosis and prevention is driving immunoassay adoption. The growing prevalence of infectious and chronic diseases is accelerating demand for advanced diagnostic solutions.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to its advanced healthcare infrastructure and strong regulatory framework. The presence of leading diagnostic companies and research institutions accelerates innovation in immunoassay technologies. Increasing healthcare expenditure and government initiatives supporting precision medicine are driving market expansion. The rising burden of chronic diseases and demand for early diagnostic solutions are fuelling immunoassay adoption.

Key players in the market

Some of the key players profiled in the Immunoassay Market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific Inc., bioMerieux SA, DiaSorin S.p.A., Becton, Dickinson and Company (BD), Sysmex Corporation, Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, PerkinElmer Inc., QIAGEN N.V., Merck KGaA, and Fujirebio, Inc.

Key Developments:

In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd's largest corporate gifts in recent history - a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

In July 2024, Siemens Healthineers, a leading medical technology company, announced that the Multix Impact E digital radiography X-ray machine will now be manufactured in India, marking a significant milestone in the company's commitment to providing better access to care for patients in the country.

Product Types Covered:

• Reagents & Kits
• Analyzers
• Software & Services
• Other Product Types

Platforms Covered:

• Laboratory-Based
• Point-of-Care (POC) Testing

Technologies Covered:

• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chemiluminescence Immunoassays (CLIA)
• Fluorescence Immunoassays (FIA)
• Radioimmunoassay (RIA)
• Lateral Flow Assays
• Others Technologies

Specimen Types Covered:

• Blood
• Urine
• Saliva
• Other Specimens

Applications Covered:

• Infectious Diseases
• Therapeutic Drug Monitoring
• Oncology
• Autoimmune Diseases
• Cardiology
• Endocrinology
• Other Applications

End Users Covered:

• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Blood Banks
• Home Care Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Immunoassay Market, By Product Type

• 5.1 Introduction
• 5.2 Reagents & Kits
  • 5.2.1 ELISA Kits
  • 5.2.2 Rapid Test Kits
  • 5.2.3 Western Blot Kits
  • 5.2.4 PCR-based Kits
• 5.3 Analyzers
  • 5.3.1 Open-Ended Systems
  • 5.3.2 Closed-Ended Systems
• 5.4 Software & Services
  • 5.4.1 Data Management Software
  • 5.4.2 Maintenance Services
  • 5.4.3 Validation & Custom Services
• 5.5 Other Product Types

6 Global Immunoassay Market, By Platform

• 6.1 Introduction
• 6.2 Laboratory-Based
• 6.3 Point-of-Care (POC) Testing

7 Global Immunoassay Market, By Technology

• 7.1 Introduction
• 7.2 Enzyme-Linked Immunosorbent Assay (ELISA)
• 7.3 Chemiluminescence Immunoassays (CLIA)
• 7.4 Fluorescence Immunoassays (FIA)
• 7.5 Radioimmunoassay (RIA)
• 7.6 Lateral Flow Assays
• 7.7 Others Technologies

8 Global Immunoassay Market, By Specimen Type

• 8.1 Introduction
• 8.2 Blood
• 8.3 Urine
• 8.4 Saliva
• 8.5 Other Specimens

9 Global Immunoassay Market, By Application

• 9.1 Introduction
• 9.2 Infectious Diseases
• 9.3 Therapeutic Drug Monitoring
• 9.4 Oncology
• 9.5 Autoimmune Diseases
• 9.6 Cardiology
• 9.7 Endocrinology
• 9.8 Other Applications

10 Global Immunoassay Market, By End User

• 10.1 Introduction
• 10.2 Hospitals & Clinics
• 10.3 Diagnostic Laboratories
• 10.4 Academic & Research Institutes
• 10.5 Pharmaceutical & Biotechnology Companies
• 10.6 Blood Banks
• 10.7 Home Care Settings
• 10.8 Other End Users

11 Global Immunoassay Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Abbott Laboratories
• 13.2 F. Hoffmann-La Roche Ltd.
• 13.3 Siemens Healthineers
• 13.4 Danaher Corporation
• 13.5 Thermo Fisher Scientific Inc.
• 13.6 bioMerieux SA
• 13.7 DiaSorin S.p.A.
• 13.8 Becton, Dickinson and Company (BD)
• 13.9 Sysmex Corporation
• 13.10 Bio-Rad Laboratories, Inc.
• 13.11 QuidelOrtho Corporation
• 13.12 PerkinElmer Inc.
• 13.13 QIAGEN N.V.
• 13.14 Merck KGaA
• 13.15 Fujirebio, Inc.